Member Info for Tillywhiz

Pre market looking blue 👍

Fresh session , for all invested as the Hemo road map unfolds through clinical 👍

Morning all invested especially LTH like myself 👍

Agree with Pawking , these boards are awash & a stage for narcissistic individuals, wannabe failed traders , disruptors who reek of agenda , one will go & another arrives ,but won’t stop the forward map of Hemo & potential stock re rate .

Transformational year for Hemo , 👍 with the forward map of the science plan & subsequent stock price reward beginning its journey north based on results & potential pharma deals .

Listed below are the last 12 month RNS in reverse order with housekeeping & placing removed - shows a clear forward map of

Hemo science & clinical plan , & look how far we have come 👍

8th Sep 2025 7:00 am RNS Manufacturing Partnership with Made Scientific

15th Aug 2025 7:00 am RNS Third Patient Treated with HG-CT-1 CAR-T Therapy

16th Jul 2025 7:00 am RNS Hemogenyx Awarded Grant

17th Jun 2025 7:00 am RNS Clearance to Proceed with Pediatric Expansion

3rd Jun 2025 7:00 am RNS Second Patient Passes Initial Safety Tests

14th May 2025 7:00 am RNS-R Pediatric Amendment to Clinical Protocol

2nd May 2025 7:00 am RNS Second Patient Treated with HG-CT-1 CAR-T Therapy

28th Apr 2025 7:00 am RNS Final Results

3rd Apr 2025 7:00 am RNS-R FDA Annual Report

24th Mar 2025 7:00 am RNS First Patient Safety

17th Mar 2025 7:00 am RNS Recruitment of Second Patient for Clinical Trials

11th Mar 2025 7:00 am RNS Institutional investment

24th Feb 2025 7:00 am RNS First-in-Human Treatment with HG-CT-1

30th Dec 2024 7:00 am RNS Opening of First Clinical Site

19th Dec 2024 7:00 am RNS Ultrafast CAR-T Manufacturing

9th Dec 2024 7:00 am RNS Site Initiation Visit Completed

6th Dec 2024 7:00 am RNS CBR Macrophage Delivery Update

22nd Nov 2024 7:00 am RNS IRB Approval for Phase I Clinical Trial

11th Nov 2024 7:00 am RNS Institutional Investment

30th Oct 2024 7:00 am RNS Schedule for Phase I Clinical Trial Opening

2nd Oct 2024 11:19 am RNS Strategic Investment from Prevail Partners, LLC

9th Sep 2024 7:00 am RNS FLT3 Assay Ready for Phase I Trials at MD Anderson

2nd Sep 2024 7:00 am RNS CDX Development Update

Good luck to all invested & may the trajectory north continue 👍👍🍷

With a low average & a large holding & I’m currently enjoying the fruits of patient investing 👍👍👍

Health before wealth

Updated Shorts

Current stock on loan / shorts 🤔😂

Shorts

25,000 stock on loan

( someone took a 3,000 short out on Friday pm 👎 )

22,000 on loan on Thursday last

Value £194,000

Cost to borrow 11%

Days to cover 0.29

Looks like someone perhaps new an RNS was coming today & opened a short Friday perhaps hoping for bad news , unlucky

If sceptical which I am , trading groups trying to fleece Hemos volatility in both directions & perhaps even associated to some of the dung spreaders on these forums . 👎

+ 500% in a couple of weeks 👍🍷

Dave & all

I will have to check time stamp of each kipper & prices at that time ask / bid

Good volume & loaded with kippers 👍

Hemo news spreading , 👍

Biopharmaceutical group Hemogenyx Pharmaceuticals plc (LSE: HEMO) announced on Monday that it has entered a manufacturing partnership with US-based contract development and manufacturing organisation

Made Scientific to advance its autologous CAR-T therapy, HG-CT-1, for relapsed/refractory acute myeloid leukaemia (r/r AML).

Made Scientific will provide technology transfer and manufacturing services from its GMP facilities in Newark and Princeton, New Jersey, which are equipped for both clinical and commercial-scale cell therapy supply.

The collaboration is expected to accelerate Hemogenyx's ongoing Phase I clinical trial in adult r/r AML patients and support potential expansion into paediatric cohorts.

Hemogenyx has reported encouraging early clinical data for HG-CT-1, reinforcing confidence in the therapy's safety and potential efficacy.

Headquartered in London with operations in New York, Hemogenyx Pharmaceuticals is developing novel treatments for blood and autoimmune diseases. Made Scientific, backed by South Korea's GC Corporation, specialises in the development and manufacturing of autologous and allogeneic cell therapies.

After today Got to be worth a glass of throat massager 🍷👍

Delayed printed trades some sizeable kippers for sure 👍🍷

08-Sep-25 16:26:15 882.48 2,000 Unknown* 900.00 920.00 17.65k O

08-Sep-25 16:18:14 897.96 2,769 Unknown* 900.00 920.00 24.86k O

08-Sep-25 14:39:56 887.0957 6,000 Unknown* 900.00 920.00 53.23k O

08-Sep-25 10:51:54 988.00 13,292 Unknown* 900.00 920.00 131.32k O

08-Sep-25 13:12:23 911.665 4,565 Unknown* 900.00 920.00 41.62k O

08-Sep-25 08:11:51 962.8643 5,166 Unknown* 900.00 920.00 49.74k O

08-Sep-25 09:42:06 1,039.50 4,000 Unknown* 900.00 920.00 41.58k O

08-Sep-25 08:06:05 875.00 5,000 Unknown* 900.00 920.00 43.75k O

08-Sep-25 15:10:35 932.60 3,000 Unknown* 900.00 920.00 27.98k O

08-Sep-25 16:04:27 893.17241 1,727 Unknown* 900.00 920.00 15.43k O

08-Sep-25 16:01:29 910.00 1,868 Unknown* 900.00 920.00 17.00k O

08-Sep-25 14:55:11 911.00 4,543 Unknown* 900.00 920.00 41.39k O

08-Sep-25 15:49:22 904.4879 2,422 Unknown* 900.00 920.00 21.91k

Bring the clinical p3 update 👍🍷

Closing price - 9.18

Vol 350,000

Vwap 9.72

Superb RNS & another 20 % added ,

500%+ up in 2 week 👍

Transformational year for Hemo , 👍

For me it’s the science & success in the clinical trials + potential pharma deal will be the huge stock driver .👍🍷

However very satisfied nibbling at a £10 per share for now . 👍

Current live £1045 - £1067

Vwap climbing £9.80

Volume 145,000 huge

MM sat @ £14.70

Superb for all invested especially lth 🍷👍

i’m a very lth but have a low average as bought a **** load at 1.3/1.4

all lth will be rewarded if science ticks all the boxes , whatever your average imo

fetch the hemo grog 🍷👍

MM sat @ £14.90 who would have thought that a month ago 🤔👍🍷

+34%

Vwap 9.70 & rising steady 👍

MM sat £11.40 🤔🍷👍

Heavy volume 75,000 traded in 30 mins

Fetch the Hemo grog 🍷👍

JFTH & all

Current stock on loan / shorts

22,000 in stock. 🤔😂👎

A few margin calls & sphincter nipping

Fetch the Gemo Grog

Superb news for all invested 👍🍷

Great RNS supporting Hemo science, been in here many yrs & great to see

Heavy volume will likely continue

Crank open the Hemo Grog 🍷👍

A substantial pharma offer /takeover , & i certainly would accept & sail off into the sunset , ⛴️

& take the ladies naked Brazilian Olympic Mud wrestling team with me on deck 🤔 & Nigella Lawson doing her porn style cooking plastered on grog in the galley 😂👍

Bring on the Hemo Pharma deal whenever that maybe 🍷👍

Morning all invested

The full English with all the trimmings so much tastier with Hemo sat @ £7.60 with expected P3 results on the breeze .👍

Hemo on Ortex today 👍

Hemogenyx Pharmaceuticals, trading under the ticker HEMO, boasts a market capitalization of approximately $51.37 million. Operating within the biotech sector, the company is involved in the development of novel therapies.

As a player in a highly dynamic and innovative industry, Hemogenyx's market cap reflects its current financial standing and market perception.

The biotech sector is known for its cutting-edge research and potential for groundbreaking treatments, positioning companies like Hemogenyx at the forefront of medical advancement.

👍👍

Vlad quote from RNS

‘ demonstrates this confidence and shows that the investors see considerable upside potential in our share price as we advance HG-CT-1 through clinical development"."

Been here yrs & have a low average 👍

Transformational year for Hemo , 👍 with the forward map of the science plan highlighted in the last 12 month RNS & subsequent stock price reward beginning its journey north based on results & potential pharma deals .👍👍

+400% in a week or so in heavy volume with volatility 👍

Would perhaps expect some sort of RNS in coming week & hopefully a cracker for all invested .👍🍷

Week ahead looking interesting 👍

Morning all invested - superb week + 300% + 👍🍷

Hemo on Ortex this morning 👍👍

Hemogenyx Pharmaceuticals, trading under the ticker HEMO, boasts a market capitalization of approximately $51.37 million. Operating within the biotech sector, the company is involved in the development of novel therapies.

As a player in a highly dynamic and innovative industry, Hemogenyx's market cap reflects its current financial standing and market perception.

The biotech sector is known for its cutting-edge research and potential for groundbreaking treatments, positioning companies like Hemogenyx at the forefront of medical advancement. 👍👍

Stock at - £7.58

Volume for week 2 million +

MCap £51 million - institutions on the sniff

Clinical trials & pharma deal are what I’m here for & & any volatility allows additional top ups 👍 & hopefully news incoming this week 👍👍🍷

Must be an exciting so called holiday if Pumpky is spending a Friday evening whinging on here when doesn’t own any stock

5p my ar5e , Karma indeed .

Shorts for the record -

A large short was taken out at 1.4 -1.7 3 weeks ago - so they are fooked

Since then

15k Monday

2k yesterday

Total 22,000 in stock

Approx £150,00 in loaned stock as of yesterday.

Good evening to all actual investors after a great week 👍🍷

JFTH & all

Current stock on loan / shorts 🤔😂

Shorts

22,000 on loan

Value £150, 000

Cost to borrow 10%

Days to cover 0.27

Oh dear , +35% , looks like a few nipping Shorters sphincters. # margin call